GlassScriptPhysician profile
Danielle Deel Traweek
NPI 1083398242
$4,957.84
in general payments reported to CMS, 2019-2025
42 companies · $2,535 in 2025
The $2,535 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $691 · 2024: $1,732 · 2025: $2,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,767 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,766.85 |
| Education | $190.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $610.21 | 2023-2025 | Darzalex, Erleada, Tecvayli |
| Daiichi Sankyo INC. | $342.95 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Abbvie INC. | $276.15 | 2024-2025 | |
| Incyte Corporation | $263.30 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Merck Sharp & Dohme LLC | $203.42 | 2023-2025 | Keytruda, Welireg, Reblozyl |
| Genentech USA, INC. | $199.54 | 2023-2025 | Tecentriq, Polivy, Phesgo |
| Astrazeneca Pharmaceuticals LP | $195.07 | 2023-2025 | Lynparza, Enhertu, Imfinzi |
| Exelixis INC. | $177.06 | 2024-2025 | Cabometyx |
| Eisai INC. | $175.57 | 2023-2025 | |
| Stemline Therapeutics INC. | $160.00 | 2023-2025 | Orserdu |
| Bayer Healthcare Pharmaceuticals INC. | $155.58 | 2023-2025 | |
| Pfizer INC. | $150.15 | 2023-2025 | |
| Astellas Pharma US INC | $143.63 | 2023-2025 | Vyloy, Padcev, Xtandi |
| Lilly USA, LLC | $141.06 | 2023-2025 | Jaypirca, Verzenio |
| Pharmaessentia USA Corporation | $139.31 | 2023-2025 | Besremi |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $137.81 | 2023-2025 | |
| Glaxosmithkline, LLC. | $123.85 | 2024-2025 | Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $96.60 | 2023-2025 | Ninlaro, Iclusig, Fruzaqla |
| Alexion Pharmaceuticals, INC. | $95.62 | 2023-2025 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $92.99 | 2024-2025 | Libtayo, Lynozyfic |
| E.R. Squibb & Sons, L.L.C. | $91.74 | 2023-2025 | Opdivo |
| Beigene USA, INC. | $88.19 | 2024-2025 | Brukinsa |
| Servier Pharmaceuticals LLC | $81.77 | 2024-2025 | |
| Beone Medicines USA, INC. | $81.30 | 2025 | Brukinsa |
| Celgene Corporation | $80.96 | 2023-2025 | Reblozyl |
| Genzyme Corporation | $72.34 | 2023-2025 | |
| Emd Serono, INC. | $70.82 | 2023-2025 | Bavencio |
| Ipsen Biopharmaceuticals, INC | $62.90 | 2024-2025 | Onivyde, Somatuline Depot |
| Sobi, INC | $61.20 | 2025 | |
| Tersera Therapeutics LLC | $58.63 | 2024-2025 | Zoladex |
| Adaptive Biotechnologies Corporation | $53.57 | 2023-2024 | Clonoseq |
| Pharmacosmos Therapeutics INC. | $49.07 | 2024-2025 | Cosela, Monoferric |
| Novartis Pharmaceuticals Corporation | $41.98 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $39.70 | 2025 | |
| Recordati_rare_diseases_inc. | $23.85 | 2024 | Sylvant |
| Rigel Pharmaceuticals, INC. | $23.65 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Geron Corporation | $20.71 | 2025 | Rytelo |
| Mirati Therapeutics, INC. | $16.62 | 2023 | Krazati |
| Adc Therapeutics America, INC. | $16.39 | 2023 | |
| Agios Pharmaceuticals, INC. | $14.93 | 2025 | Pyrukynd |
| Azurity Pharmaceuticals, INC. | $13.93 | 2025 | Vivimusta, Danziten |
| Seagen INC. | $13.72 | 2023 | Tukysa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Traweek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.